Second Genome brings microbiome science to the discovery and development of therapeutic products. The company has established a pipeline of microbiome modulators that impact infection, immunity and metabolic diseases. Second Genome’s development pipeline is fueled by novel technologies for identifying, screening and scientifically validating product candidates and microbial biomarkers. Second Genome’s technologies have been rigorously validated through partnerships with leading pharmaceutical and nutrition companies, as well as academic and governmental research institutions.
Second Genome has assembled a leadership team with the capabilities to leverage the microbiome for research and development. Second Genome was founded on groundbreaking science from Lawrence Berkeley National Laboratory with the support of veteran biotechnology entrepreneurs. Second Genome has attracted a world-class scientific advisory board comprised of renowned experts that have paved the way on how changes in the human microbiome impact illnesses such as obesity, diabetes, asthma, inflammatory diseases and digestive diseases. The company is backed by investors with a track record of value creation, including Advanced Technology Ventures and Morgenthaler Ventures.